Introduction
L oco-regional therapy is a crucial cog in the multidisciplinary management of cervical cancer of all stages. There has been a substantial improvement in outcomes. However, loco-regional failure rate of 41%-72% in locally advanced stage of carcinoma cervix with radiotherapy (RT) alone to achieve high local control is the primary requirement. [1, 2] Once local control achieved, survival benefit expected to increase to be 50-60%. [3, 4] Cisplatin-based chemoradiation has improved the survival around 23%, with a median survival of 6-8 months, and is considered a standard radiation are sensitive to HT. HT sensitizes the effects of radiation by interfering with repair of DNA damage. [9] Mild HT may also increase perfusion and oxygenation which may, in turn, lead to increased sensitivity to radiation therapy. [10] The therapeutic benefit observed with the addition of HT was at a cost of limited HT-induced toxicity, whereas radiation-induced toxicity remains unaffected. Combining HT with RT has shown improved response rate and tumor control in many randomized trials. [11] [12] [13] [14] 
Materials and Methods

Patients
Files of patients with confirmed diagnosis of carcinoma cervix with histology of squamous cell carcinoma were opened. A total of 20 patients who received RT and HT with or without CT with stages the International Federation of Gynaecology and Obstetrics from I to IVA were included in this study. Patients with metastasis were excluded from study. All patients had given the consent before starting the treatment. 
Radiotherapy
Hyperthermia
Along with EBRT, all patients were prescribed once a week or twice a week HT for 5 weeks. For HT, the treatment time was 40 min and intratumor temperature was above 42°C. Intrapelvic temperature was kept high and homogenous as per patients' tolerance limit. Once patient complained about uncomfortable feelings, treatment settings such as phase, amplitude, frequency, and power were adjusted accordingly. Pulse and blood pressure were measured before and every 5 min during treatment. HT machine used was YAMAMOTO Model: T-RF8.
Study design
The present study is a retrospective analysis of cancer cervix patients treated with RT and HT with or without CT. The study period was from January 2012 to January 2018. The study area was Advanced Centre of Radiation Oncology Department in Nanavati Super Speciality Hospital, Vile Parle, Mumbai. During this period, 20 patients received RT along with HT. Primary endpoint of the study was complete response and overall survival. A complete response was defined as disappearance of all tumors in the irradiated volume; this was established 3 months after treatment. Response was assessed by physical examination, and if indicated, supplemental investigations were done. Overall survival was defined as the time between randomization and death or last follow-up. Secondary endpoint was recurrence-free survival (RFS) and defined as length of time after primary treatment for cancer end that the patient survive without any signs and symptoms of that cancer.
Statistical methods
Data were presented as mean ± standard deviation, median (range), and frequency (percentage). Kaplan-Meier survival analysis was used as univariate analysis. For univariate analysis, variables such as age, stage, technique, CT, response, boost required, and HT fraction were compared with Kaplan-Meier method and compared using log rank test. Factors associated with the 
Discussion
HT with RT has been explored in cancer cervix. HT at 39-43°C is a potent radio-and chemo-sensitizer. [7, 8, 10] This is may be particularly relevant in locally advanced cancer cervix cases which are known to harbor a significant population of radioresistent hypoxic cells. [9] Recently, a number of studies adding CT to RT and HT have been published, and some of these trials compared RT + CT + HT outcomes with RT + CT which is preferred therapeutic option for locally advanced carcinoma cervix. The present study is a retrospective analysis of carcinoma cervix patients treated with either RT + HT or RT + HT + CT.
In our study, the mean age was 54 years; similarly, in Dutch deep HT, the trial mean age was 50 years. [15] [16] [17] Approximately 65% patients were from Stage III and IV. In a meta-analysis of RT + HT versus RT, Datta et al. observed maximum number of patients had locally advanced Stage III and IV. [18] Similarly, in Cochrane review, Lutgens et al. reported that higher number of patients were of locally advanced stage of cancer cervix. [19] In a meta-analysis reported by Yan et al., they also noticed that Stage III and IV were predominant. [20] In the present study, the technique included were both 3DRT and IMRT. 65% patients were treated with 3DRT and 35% patients received IMRT. In recent few years, IMRT has gain popularity because of sparing of organ at risk and precise dose to target approach.
After completion of EBRT, 65% patients received boost via brachytherapy and 20% with EBRT in the present study. 15% patients did not report for boost of primary disease at cervix. In a study, Franckena et al. also observed that 87% patients were treated via brachytherapy boost and 13% patients did not receive brachytherapy boost. [17] In response assessment, this retrospective study shows that 75% patients had complete response. Datta et al.
also showed similar 74% complete response in locally advanced cancer cervix patients treated with RT and HT. [21] Similarly, Franckena et al. in a study observed that 83% of patients in the RT + HT group (48/58) achieved a complete response and 57% (32/56) in the RT group (P = 0.03). At follow-up, the difference in pelvic tumor control was sustained with 5-year pelvic tumor control rates of 61% in the RT + HT group and 37% in the RT group. At 12 years, the pelvic tumor control rate was 56% in the RT + HT group and remained 37% in the RT-group. [17] This difference was significant (P = 0.01). Chen et al. and Harima et al. also observed 72% and 80% complete response in their studies, respectively. [22, 23] Pelvic tumor control with RT and HT was 70% in a study by Sharma et al. [24] Similarly, Vasantha et al. also observed that pelvic tumor control at 3 years in locally advanced cancer cervix was 70% patients treated with RT and HT. [25] Three randomized trials also show improved overall survival with RT and HT compared to RT alone. Datta et al. observed that 2-year overall survival was 81% with RT + HT while 73% with RT only. [21] Harima et al. and Vasantha et al. also noticed that 3-year overall survival was 58% and 73%, respectively, when HT added to RT. [23, 25] In an update of Dutch deep HT trial, Franckena et al. studied long-term outcomes after RT and HT in locally advanced carcinoma cervix. They described overall survival at 12 years was 37% in RT + HT group and 20% in RT-alone group (P = 0.03). The median overall survival was 2.64 years in the RT + HT group and 1.78 years in the RT group. In a multivariate analysis, the treatment arm remained an independent prognostic factor with a significant advantage in overall survival after RT + HT (P = 0.03, HR 0.60, 95% CI 0.38-0.95). [17] Similar to these studies in our retrospective analysis, the mean overall survival was 46.98 (32.60-61.36) months, with a median follow-up time of 22 months (6-72 months). The estimated 1 year, 2 years, 3 years and above yearly estimates were 89.7%, 65.9%, and 54.9%, respectively. On univariate analysis, we have significant impact of HT fractions with (HR = 4.32 [95% CI 0.86-21.48], P = 0.049). On multivariate analysis, we had near about significance for HT fractions on overall survival.
In Dutch deep HT update, Franckena et al. observed 25% pelvic recurrences in RT + HT group while it was 31% in RT-alone group. [17] This difference was not significant. Similar to this in our study, pelvic recurrence was 20% (4/20) while RFS was 41.7 months. The estimated 1 year, 2 years, and 3 years and above yearly RFS estimates are 68.8%, 57.4%, and 47.8%, respectively. For RFS, none factor was significant. Similar to above-mentioned all trials, our retrospective study also shows improved local response and overall survival when HT added to locally advanced carcinoma cervix patients.
Conclusion
Combination of HT and RT shows better overall survival in patients of carcinoma cervix. HT is a good option in patients with locally advanced carcinoma cervix who are not eligible for CT. However, further studies are required to establish the role of HT in other patients of locally advanced carcinoma cervix.
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